Search results for "AMYLOIDOSIS"

showing 10 items of 79 documents

Imaging P-Glycoprotein Induction at the Blood–Brain Barrier of a β-Amyloidosis Mouse Model with 11C-Metoclopramide PET

2019

P-glycoprotein (ABC subfamily B member 1, ABCB1) plays an important role at the blood–brain barrier (BBB) in promoting clearance of neurotoxic β-amyloid (Aβ) peptides from the brain into the blood. ABCB1 expression and activity were found to be decreased in the brains of Alzheimer disease patients. Treatment with drugs that induce cerebral ABCB1 activity may be a promising approach to delay the build-up of Aβ deposits in the brain by enhancing clearance of Aβ peptides from the brain. The aim of this study was to investigate whether PET with the weak ABCB1 substrate radiotracer 11C-metoclopramide can measure ABCB1 induction at the BBB in a β-amyloidosis mouse model (APP/PS1-21 mice) and in w…

Pregnane X receptorMetoclopramidebiologybusiness.industryActivator (genetics)AmyloidosisPharmacologyBlood–brain barriermedicine.disease03 medical and health sciences0302 clinical medicinemedicine.anatomical_structure030220 oncology & carcinogenesisbiology.proteinMedicineImmunohistochemistryRadiology Nuclear Medicine and imagingAlzheimer's diseasebusiness030217 neurology & neurosurgerymedicine.drugP-glycoproteinJournal of Nuclear Medicine
researchProduct

Human apolipoprotein A-I natural variants: molecular mechanisms underlying amyloidogenic propensity

2012

Human apolipoprotein A-I (apoA-I)-derived amyloidosis can present with either wild-type (Wt) protein deposits in atherosclerotic plaques or as a hereditary form in which apoA-I variants deposit causing multiple organ failure. More than 15 single amino acid replacement amyloidogenic apoA-I variants have been described, but the molecular mechanisms involved in amyloid-associated pathology remain largely unknown. Here, we have investigated by fluorescence and biochemical approaches the stabilities and propensities to aggregate of two disease-associated apoA-I variants, apoA-IGly26Arg, associated with polyneuropathy and kidney dysfunction, and apoA-ILys107-0, implicated in amyloidosis in severe…

ProteomicsProtein Foldinglcsh:MedicineProtein aggregationpolymyxinsBiochemistryProtein Structure SecondaryMiceProtein structureneutrophilsMolecular Cell Biologypolycyclic compoundslcsh:ScienceCellular Stress ResponsesMultidisciplinaryProtein StabilityAmyloidosisCiencias QuímicasfluorescenseCell biologymacrophagesBiochemistryToxicityMedicineProtein foldinglipids (amino acids peptides and proteins)medicine.symptomPolyneuropathyResearch ArticleProtein StructureMedicinaLipoproteinsImmunologyBiophysicsInflammationAmyloidogenic ProteinsBiologyProtein ChemistryMicrobiologyCell Lineprotein aggregationmacrophage activationmedicineAnimalsHumansoligomersProtein InteractionsBiologyInflammationamyloidosisApolipoprotein A-IMacrophageslcsh:RImmunityProteinsnutritional and metabolic diseasesmedicine.diseaseApolipoproteinsAmino Acid SubstitutionCell cultureinflammationCiencias Médicaslcsh:QClinical ImmunologyMutant ProteinspolyneuropathyProtein Multimerization
researchProduct

Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic Area

2015

Abstract Background: Familial amyloid polyneuropathy related to transthyretin gene (TTR-FAP) is a life-threatening disease transmitted as an autosomal dominant trait. Val30Met mutation accounts for the majority of the patients with large endemic foci especially in Portugal, Sweden and Japan. However, more than one hundred other mutations have been described worldwide. A great phenotypic variability among patients with late- and early-onset has been reported. Objective: To present a detailed report of TTR-FAP patients diagnosed in our tertiary neuromuscular center, in a 20-year period. Methods: Clinical informations were gathered through the database of our center. Results: The study involve…

Research ReportPediatricsmedicine.medical_specialtyPathologydysautonomiaCardiomyopathyLate onsetTTRtransthyretinmedicineFamilial amyloid polyneuropathy FAP transthyretin TTR amyloidosis cardiomyopathy dysautonomia epidemiology Italyamyloidosisbiologybusiness.industryAmyloidosisDysautonomiaAutosomal dominant traitFAPmedicine.diseaseTransthyretinPeripheral neuropathyNeurologyItalyFamilial amyloid polyneuropathybiology.proteinepidemiologyNeurology (clinical)medicine.symptombusinessPolyneuropathycardiomyopathyJournal of Neuromuscular Diseases
researchProduct

Comparison of Right Ventricular Longitudinal Strain Imaging, Tricuspid Annular Plane Systolic Excursion, and Cardiac Biomarkers for Early Diagnosis o…

2010

Objectives: The aim was to determine the role of assessing right ventricular (RV) function, using standard echocardiography and Doppler myocardial imaging (DMI), in the early diagnosis of cardiac amyloidosis (CA) and in prediction of mortality. Methods: A total of 249 patients with AL amyloidosis were categorized on the basis of left ventricular thickness and E' velocity, and compared to 38 age- and sex-matched controls. Standard echocardiographic parameters of RV function were assessed, and longitudinal systolic myocardial velocity, strain rate (sSR), and strain (sS) were determined for the basal and middle RV free wall segments. Patients were followed for the endpoint of mortality. Result…

Settore MED/09 - Medicina InternaCardiac Amyloidosis Echocardiography Cardiac biomarkers
researchProduct

Familial amyloidosis: great progress for an orphan disease.

2015

Familial amyloidosis: Great progress for an orphan disease Ana Paula Barreiros1,2,*, Gerd Otto3, Bita Kahlen1, Andreas Teufel1,2, Peter R. Galle1 1Department of Internal Medicine I, Universitatsmedizin of the Johannes Gutenberg-University Mainz, Germany; 2Department of Internal Medicine I, Universitatsklinikum of the University Regensburg, Germany; 3Department of Hepatobiliary and Transplantation Surgery, Universitatmedizin of the Johannes Gutenberg-University Mainz, Germany. *Corresponding author. Address: Universitatsklinikum Regensburg, Department of Internal Medicine I, Franz-Josef-Strauss Allee 11, 93053 Regensburg, Germany. Tel.: +49 941-944-7021. E-mail address: Ana.Barreiros@ukr.de …

TafamidisFamilial amyloidosismedicine.medical_specialtyPathologyPharmacological therapymedicine.medical_treatmentDiseaseLiver transplantationGlobal Healthchemistry.chemical_compoundRare DiseasesMedicineHumansTransplantation surgeryLiver transplantationHepatologybusiness.industryGeneral surgerymusculoskeletal neural and ocular physiologyDisease ManagementPharmacological therapymedicine.diseaseTafamidissurgical procedures operativechemistryGERDMorbiditybusinessFamilial amyloidosisAmyloidosis FamilialJournal of hepatology
researchProduct

Use of drugs for attrv amyloidosis in the real world: How therapy is changing survival in a non-endemic area

2021

Background: Over the past decade, three new drugs have been approved for the treatment of hereditary amyloid transthyretin (ATTRv) polyneuropathy. The aim of this work was to analyze whether current therapies prolong survival for patients affected by ATTRv amyloidosis. Methods: The study was conducted retrospectively, analyzing the medical records of 105 patients with genetic diagnoses of familial amyloidotic polyneuropathy followed at the two referral centers for the disease in Sicily, Italy. Of these, 71 received disease-modifying therapy, while 34 received only symptomatic treatment or no therapy. Results: The most used treatment in our patient cohort was tafamidis, followed by liver tra…

Tafamidismedicine.medical_specialtySurvivalmedicine.medical_treatmentHereditary transthyretin amyloidosisNeurosciences. Biological psychiatry. NeuropsychiatryDisease030204 cardiovascular system & hematologyLiver transplantationArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNon-V30MInternal medicineATTRvPolyneuropathyMedicineATTRv; hereditary transthyretin amyloidosis; inotersen; non-V30M; patisiran; polyneuropathy; survival; tafamidis; patisiran; inotersenbiologybusiness.industryGeneral NeuroscienceAmyloidosisMedical recordmedicine.diseaseTafamidisTransthyretinchemistryCohortbiology.proteinPatisiranSettore MED/26 - NeurologiabusinessPolyneuropathy030217 neurology & neurosurgeryRC321-571Inotersen
researchProduct

α-Synuclein expression levels do not significantly affect proteasome function and expression in mice and stably transfected PC12 cell lines

2004

α-Synuclein (α-syn) is a small protein of unknown function that is found aggregated in Lewy bodies, the histopathological hallmark of sporadic Parkinson disease and other synucleinopathies. Mutations in the α-syn gene and a triplication of its gene locus have been identified in early onset familial Parkinson disease. α-Syn turnover can be mediated by the proteasome pathway. A survey of published data may lead to the suggestion that overexpression of α-syn wild type, and/or their variants (A53T and A30P), may produce a decrease in proteasome activity and function, contributing to α-syn aggregation. To investigate the relationship between synuclein expression and proteasome function we have s…

Time Factorsanimal diseasesmedicine.disease_causePC12 CellsBiochemistryMicechemistry.chemical_compoundTransgenesPromoter Regions GeneticMice KnockoutGeneticsMutationInnervationBrainParkinson DiseaseProteasome complexAmyloidosisCell biologyInnervacióalpha-SynucleinAdditions and CorrectionsPèptidsPlasmidsProteasome Endopeptidase ComplexPrionsProtein subunitBlotting WesternImmunoblottingSynucleinsMice TransgenicNerve Tissue ProteinsBiologyTransfectionBacterial ProteinsMultienzyme ComplexesmedicineAnimalsImmunoprecipitationMolecular BiologyAlpha-synucleinSynucleinopathiesEpilepsyWild typeGenetic VariationCell BiologyAxonsRatsnervous system diseasesMice Inbred C57BLEpilèpsiaDisease Models AnimalLuminescent ProteinschemistryProteasomenervous systemSinapsiMutationSynapsesSynucleinAmiloïdosiPeptides
researchProduct

Clinical symptomatic de novo systemic transthyretin amyloidosis 9 years after domino liver transplantation

2009

Four years ago, Stangou et al. reported a patient who developed clinical symptoms of amyloidosis 8 years after domino liver transplantation (DLT). In order to alleviate the graft shortage, livers from patients with familial amyloidotic polyneuropathy (FAP) are used as domino grafts for other patients under the assumption that several decades will pass before clinical symptoms due to amyloid accumulation emerge. We now report on another case, the third reported case in the literature, of de novo systemic amyloidosis in a 75-year-old woman 9 years after DLT. The patient underwent DLT at 65 years of age for hepatocellular carcinoma exceeding the Milan criteria in hepatitis C cirrhosis. Transar…

Transplantationmedicine.medical_specialtyPathologyCirrhosisDysesthesiaHepatologybusiness.industrymedicine.medical_treatmentAmyloidosisHepatitis CLiver transplantationMilan criteriamedicine.diseaseSurgeryB symptomsMedicineSurgerymedicine.symptombusinessPolyneuropathyLiver Transplantation
researchProduct

Progression of transthyretin (TTR) amyloidosis in donors and recipients after domino liver transplantation-a prospective single-center cohort study

2018

Liver transplantation (LT) is the first-line therapy in patients with transthyretin (TTR) amyloidosis and progressive familial amyloid polyneuropathy (FAP). Explanted organs from these patients can be used for domino liver transplantation (DLT). After DLT, de novo amyloidosis may develop in domino recipients (DR). Data were collected prospectively in a transplant database. Electroneurography by nerve conduction velocity (NCV), quantitative sensory testing, heart rate variability (HRV), sympathetic skin response, orthostatic reaction (tilt table test), transthoracic echocardiography, cardiac MRI and organ biopsy results were evaluated. The cohort included 24 FAP- (11 Val30Met, 13 nonVal30Met…

Transplantationmedicine.medical_specialtybiologymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentAmyloidosis030204 cardiovascular system & hematologyLiver transplantationmedicine.diseaseSingle CenterGastroenterology03 medical and health sciencesTransthyretinTilt table test0302 clinical medicineInternal medicineCohortBiopsybiology.proteinMedicinebusiness030217 neurology & neurosurgeryCohort studyTransplant International
researchProduct

Early detection of amyloid light-chain amyloidosis: a case report of oral primary manifestation

2018

amyloid light-chain amyloidosis oral manifestation
researchProduct